Charcot-Marie Tooth disease
Jul 10, 2026
The Race to Transform Charcot-Marie-Tooth Disease Treatment: Which Therapy Will Cross the Finish Line First?
Summary Charcot-Marie-Tooth disease is genetically heterogeneous, with more than 100 genes associated with different CMT disease subtypes. Currently, no approved therapies are available for the treatment of CMT disease, leaving patients with limited treatment options. As a result, there remains a significant...
Read More...
Jun 13, 2023
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result
FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...
Read More...
Feb 14, 2019
Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets
Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea is to take its major programs into IND-enabling studies for Aspartylglucosaminuria (AGU) and a rare form of Charcot-Marie Tooth disease with...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
